On-chip assay for identifying candidate microtubule binding drugs to treat adrds
Ended Project Grant Awarded Last action
- Award ID
- R43AG085842
- Recipient
-
Neuroindx UEI XS6TCKK96DR6
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $514,862
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date
- Place of performance
- California, USA
Award details come from USAspending.gov.
Description
- Abstract
- Microtubules (MTS) are structurally and functionally essential components of neurons, providing spatial organization and ensuring intracellular trafficking. MTS are chemically and functionally heterogeneous structures regulated by a complex molecular machinery that can modulate their composition, chemical modification, and propensity for binding with specific MT-associated proteins (MAPS). Dysfunctions of MAPS are directly associated with different forms of alzheimer's disease related disorders (ADRDS). This notion led to the development of compounds restoring the correct functioning of MTS and, therefore, counteracting neurodegeneration. However, currently this effort requires the use of methods that are costly, time consuming and inefficient, as IT requires the use of cell cultures and animal models. We propose to develop an on-chip functional assay for identifying candidate MT-binding drugs to treat ADRDS. Our on-chip assay will replicate key features of the neuronal MT microenvironment and will use in vitro generated MTS with kinesin based read out system to measure the ability of potential drugs to stabilize and affect MT transport. We will validate the assay using MT associated protein TAU and known MT stabilizing drugs. The phase I funding will allow US to develop a proof-of-concept on-chip assay that can be further developed in phase II. The proposed chip will provide a novel ad/adrd cell-free in vitro model system that could be used in the translation process to perform high- throughput screening for drug discovery and drug efficacy and functionally validate therapeutic target(S).
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $514,862 |
Quick answers
Who received award R43AG085842?
R43AG085842 was awarded to Neuroindx by National Institute on Aging (National Institutes of Health) on August 1, 2024.
How much is award R43AG085842 worth?
$514,862 has been obligated on R43AG085842.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award